|
Bio-Path Holdings Reports Second Quarter 2011 Financial Results
MarketWatch (press release) Bio-Path is developing a neutral lipid-based liposome delivery technology for nucleic acid cancer drugs (including antisense and siRNA molecules), a delivery technology that forms microscopic-sized vehicles to safely deliver these drugs to their ... |
Read the full story:
Bio-Path Holdings Reports Second Quarter 2011 Financial Results - MarketWatch (press release)
You must log in to post a comment.